Search
Close this search box.
    • Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Search
Close this search box.

Publications

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Promoting Catalytic C-Selective Sulfonylation of Cyclopropanols against Conventional O-Sulfonylation Using Readily Available Sulfonyl Chlorides
Publication: ACS Publications
11th Sep, 2023
Read
Characterization of acquired resistance mutations to menin inhibitors
Publication: American Association for Cancer Research
1st Apr, 2023
Read
LP-07 In silico analysis using Derek and Sarah along with ICH M7 expert review accurately predicts Mutagenicity and Carcinogenicity of Nitrosamines
Publication: Toxicology Letters
30th Aug, 2022
Read
Challenges in setting permitted daily exposure limits for pharmaceuticals: A review
Publication: National Library of Medicine; International Journal of Risk & Safety in Medicine
20th Feb, 2022
Read
Approaches for setting occupational exposure limits in the pharmaceutical industry
Publication: Journal of Applied Toxicology Wiley
21st Jun, 2021
Read
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
Publication: mAbs
17th Jul, 2022
Read
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
Publication: Journal of Medicinal Chemistry
4th Jul, 2021
Read
Potent antimalarials with development potential identified by structure-guided computational optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series
Publication: Journal of Medicinal Chemistry
19th Apr, 2021
Read
Solvent-Dependent Photophysics and Reactivity of Monomeric and Dimeric 4-Amino-1,8-Naphthalimides
Publication: The Journal of Physical Chemistry A
15th Mar, 2021
Read
Synthetic platform for mono-functionalised tridentate macrocycles as key precursors of mechanically-linked macromolecular systems
Publication: Organic Chemistry Frontiers
7th Mar, 2021
Read

Sign-up for our newsletter

© 2023. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

Close

To view or email, Please share your details view

To download, Please share your details